Allogene Therapeutics Inc (NASDAQ: ALLO): To Buy Or Not To Buy, That Is The Question
Allogene Therapeutics Inc (ALLO) concluded trading on Thursday at a closing price of $1.56, with 2.44 million shares of worth about $3.81 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -41.57% during that period and on March 27, 2025 the price saw a […]
Are Analysts Expecting A Better 2025 For Allogene Therapeutics Inc (ALLO)?
Allogene Therapeutics Inc (ALLO) concluded trading on Wednesday at a closing price of $1.69, with 5.27 million shares of worth about $8.91 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -38.77% during that period and on Wednesday the price remained unchanged. Currently the […]
Is Allogene Therapeutics Inc (NASDAQ: ALLO) Back In The Buying Zone?
Currently, there are 209.50M common shares owned by the public and among those 140.79M shares have been available to trade. The company’s stock has a 5-day price change of 35.10% and -28.17% over the past three months. ALLO shares are trading -4.23% year to date (YTD), with the 12-month market performance down to -55.75% lower. […]
Is There More Upside Ahead For Allogene Therapeutics Inc (NASDAQ: ALLO)
Allogene Therapeutics Inc (ALLO) concluded trading on Wednesday at a closing price of $4.15, with 4.08 million shares of worth about $16.92 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.95% during that period and on Wednesday February 7 the price saw a […]
Analyst Expect Big Moves From Allogene Therapeutics Inc (NASDAQ: ALLO)
Fidelity Management & Research Co recently announced the acquisition of new stake in Allogene Therapeutics Inc (NASDAQ:ALLO). The institutional investor has increased its shareholding in the Healthcare company by 0.91% to 25.14 million shares with purchase of 0.23 million shares. This fresh investment now brings its stake to 14.94% valued currently at $59.09 million. In […]
Allogene Therapeutics Inc (NASDAQ: ALLO): Hunting Genuine Value In Market Debris
Fidelity Management & Research Co recently announced the acquisition of new stake in Allogene Therapeutics Inc (NASDAQ:ALLO). The institutional investor has increased its shareholding in the Healthcare company by 0.91% to 25.14 million shares with purchase of 0.23 million shares. This fresh investment now brings its stake to 14.94% valued currently at $59.09 million. In […]
